Results for tag: "Rilonacept"

Rilonacect is a biologic drug used to treat immune disorders. It is a recombinant fusion protein that binds to interleukin-1 (IL-1) and blocks its activity. This helps to reduce inflammation and pain associated with certain immune disorders. Rilonacect is approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). It is also approved for the treatment of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). Rilonacept is administered as a subcutaneous injection once a week. It is available in both pre-filled syringes and auto-injectors. The drug is marketed by Regeneron Pharmaceuticals, Inc. in the United States and by Sanofi in the European Union. Other companies involved in the Rilonacect market include Amgen, Inc., Biogen, Inc., and Pfizer, Inc. Show Less Read more